| Symbol | MDGEF |
|---|---|
| Name | MEDIGENE AG |
| Sector | UNDEFINED |
| Region | Europe |
| Industry | - |
| Address | D-82152 Germany Lochhamer Strasse 11 |
| Telephone | +49-89-20 00 33 - 0 |
| Fax | — |
| — | |
| Website | http://www.medigene.com |
| Incorporation | DE |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: Frankfurt Stock Exchange |
| CIK | 0001137461 |
| Description | Medigene is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. Additional info from OTC: |
No news found.